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Abstract
AP-2 transcription factors are key regulators of mouse embryonic development. Aberrant expression of these genes has also been linked
to the progression of human breast cancer. Here, we have investigated the role of the AP-2 gene family in the postnatal maturation of the
mouse mammary gland. Analysis of AP-2 RNA and protein levels demonstrates that these genes are expressed in the mammary glands of
virgin and pregnant mice. Subsequently, AP-2 expression declines during lactation and then is reactivated during involution. The AP-2 and
AP-2 proteins are localized in the ductal epithelium, as well as in the terminal end buds, suggesting that they may influence growth of the
ductal network. We have tested this hypothesis by targeting AP-2 expression to the mouse mammary gland using the MMTV promoter.
Our studies indicate that overexpression of AP-2 inhibits mammary gland growth and morphogenesis, and this coincides with a rise in
PTHrP expression. Alveolar budding is severely curtailed in transgenic virgin mice, while lobuloalveolar development and functional
differentiation are inhibited during pregnancy and lactation, respectively. Our studies strongly support a role for the AP-2 proteins in
regulating the proliferation and differentiation of mammary gland epithelial cells in both mouse and human.
© 2003 Elsevier Science (USA). All rights reserved.
Keywords: Transcription factors; AP-2; AP-2; Transgenic mice; Mammary gland; Alveolar budding; Lobuloalveolar development; Breast cancer
Introduction
The AP-2 family of transcription factors regulates im-
portant aspects of vertebrate embryogenesis and has also
been linked to the control of cell proliferation and tumori-
genesis. The AP-2 proteins constitute a distinct class of
transcription factor, which is defined by the presence of a
“basic–helix–span–helix” DNA binding and dimerization
motif (Williams and Tjian, 1991a,b). To date, four AP-2
genes have been characterized in mammalian species, AP-
2, AP-2, AP-2, and AP-2 (Bosher et al., 1996;
Chazaud et al., 1996; Imagawa et al., 1987; Mitchell et al.,
1987; Moser et al., 1995; Williams et al., 1988; Zhao et al.,
2001). Considerable sequence identity exists between the
DNA binding domains of these four AP-2 proteins, and they
can all bind as homo- or heterodimers to a GC-rich element
typified by the consensus sequence 5-GCCNNNGGC-3
(Bosher et al., 1996; McPherson and Weigel, 1999; Mo-
hibullah et al., 1999). Many genes that mediate cell growth,
cell shape, cell movement, and cell communication fre-
quently possess important AP-2 binding sites as a compo-
nent of their cis-regulatory sequences (Bosher et al., 1995;
Gaubatz et al., 1995; Gille et al., 1997; McPherson et al.,
1997; Zeng et al., 1997). Indeed, the finding that genes,
including cytokeratins, E-cadherin, integrins, and matrix
metalloproteinases, are regulated by AP-2 reflects an im-
portant role for these transcription factors in morphogenesis
(Byrne et al., 1994; De Clerk et al., 1994; Fini et al., 1994;
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Hennig et al., 1996; Mitchell et al., 1987; Somasundaram et
al., 1996; Zutter et al., 1994). Currently, the AP-2, AP-2,
and AP-2 genes are the best characterized. During embry-
ogenesis, all three genes are expressed in tissues undergoing
complex morphogenetic changes, principally in the neural
crest, neural tube, kidney, eye, facial prominences, and limb
buds (Chazaud et al., 1996; Mitchell et al., 1991; Moser et
al., 1997b). The expression of the individual AP-2 genes
often coincides in particular tissues, but overall, each family
member has a unique spatiotemporal pattern of expression.
Mouse molecular genetic studies have demonstrated that
there is a critical requirement for the AP-2 genes during
mammalian development. A homozygous null mutation for
any of the AP-2 genes results in lethality either during
embryogenesis or shortly after birth. In particular, the dis-
ruption of the AP-2 gene leads to defects in the formation
of the neural tube, face, eyes, heart, and limbs during em-
bryogenesis (Brewer et al., 2002; Nottoli et al., 1998;
Schorle et al., 1996; West-Mays et al., 1999; Zhang et al.,
1996). Moreover, these AP-2 knockout mice lack a ventral
body-wall, resulting in a severe thoracoabdominoschisis.
Mice lacking the AP-2 gene die shortly after birth, due to
inappropriate morphogenesis of the kidneys (Moser et al.,
1997a), but do not display any other major developmental
abnormalities. AP-2-null mice die around E7.5, shortly
after implantation (Auman et al., 2002; Werling and
Schorle, 2002). In this instance, the defects occur within the
extraembryonic cell lineages and there is no requirement for
AP-2 in the embryo proper (Auman et al., 2002). The fact
that none of the AP-2 knockout mice survive until weaning
indicates the collective importance of the AP-2 genes, but at
present, precludes an understanding of how these genes
might regulate later developmental events, in particular
mammary gland maturation.
Although much is known about the spatiotemporal reg-
ulation of the AP-2 genes during embryogenesis, little in-
formation exists concerning their expression in the postnatal
mammary gland. Nevertheless, it is clear from studies of
human tissue samples that the AP-2 proteins can be ex-
pressed in the adult breast (Turner et al., 1998). Moreover,
several studies have indicated that the AP-2 proteins may
regulate gene expression in breast cancer (Gee et al., 1999;
Turner et al., 1998). The AP-2, AP-2, and AP-2 pro-
teins have been detected in breast cancer biopsies, and there
is a significant up-regulation of AP-2 expression in early-
stage breast tumors compared with benign tissue (Turner et
al., 1998). The presence of various combinations of the
AP-2 proteins in tumor tissue also coincides with the ex-
pression of several genes involved in cell growth and pro-
liferation. Significant correlations have been reported for
the presence of the insulin-like growth factor I receptor
(IGF-I-R) and AP-2 expression, the estrogen receptor (ER)
and AP-2, and p21waf1/cip1 and AP-2 family members (Gee
et al., 1999; Turner et al., 1998). However, the most striking
finding was that the majority of tumors containing signifi-
cant levels of ErbB2 (HER2/Neu) protein expressed both
the AP-2 and AP-2 proteins (Turner et al., 1998). The
significance of these various correlations is strengthened by
the finding that AP-2 binding sites are present within the
promoters of the human IGF-I-R, ER, p21waf1/cip1, and
ErbB2 genes (Bosher et al., 1995; McPherson et al., 1997;
Turner et al., 1998; Zeng et al., 1997). Thus, AP-2 may
regulate the transcription of these targets in human breast
cancer. Evidence obtained in vitro concerning the role of
AP-2 in cellular transformation suggests two alternative
hypotheses for the presence of increased expression of AP-2
in breast cancer (Kannan et al., 1994; Zeng et al., 1997).
One possibility is that the AP-2 proteins are proliferative
signals that activate a variety of growth factor pathways. An
alternative hypothesis is that the AP-2 proteins are more
akin to tumor suppressors, and the activation of the AP-2
genes would represent a failed attempt to halt cell prolifer-
ation. However, it has not been possible to distinguish
between these potential roles for AP-2 using the current
strains of AP-2 knockout mice, due to their early lethality.
Therefore, in the current analysis, we have generated and
analyzed transgenic mice in which the AP-2 gene is over-
expressed in the postnatal mammary gland. We have com-
bined these transgenic studies with an analysis of AP-2
expression during normal mammary gland maturation.
Taken together, our findings demonstrate that the AP-2
proteins can regulate the growth and morphogenesis of the
mammary gland. In particular, the data support the hypoth-
esis that the presence of exogenous AP-2 inhibits prolif-
eration of the ductal epithelia, and we therefore infer that the
endogenous AP-2 genes may be activated for the same
purpose in human breast cancer.
Materials and methods
Tissue collection and histological analysis
Mammary gland tissue samples were obtained by remov-
ing the fourth inguinal gland from mice at various stages of
postnatal development, i.e., from virgin, pregnant, and lac-
tating mice, and from mice in which the mammary gland
was regressing. In virgin wild-type and transgenic mice,
mammary glands were removed at equivalent stages of the
estrous cycle (Rugh, 1968). In lactating mice, the pups were
removed from the mothers 5–6 h before sacrifice and mam-
mary gland isolation. The tissue specimens were fixed with
freshly made 10% neutral buffered formalin or 4% parafor-
maldehyde, dehydrated in a graded series of ethanol and
xylene, then embedded in paraffin wax. Sections of 5 m
were cut and mounted on poly-L-lysine-coated slides. These
sections were stained with hematoxylin and eosin or used
for immunohistochemical analysis. Whole-mount analysis
of mouse mammary tissue was performed as previously
described (Wysolmerski et al., 1995). The detection of
-galactosidase activity in mouse mammary tissue was as
described (Brisken et al., 1998), and slides were counter-
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Fig. 1. Expression of the AP-2 gene family in the mouse mammary gland. (A) RNase protection analyses of AP-2 (upper panel), AP-2 (middle), and AP-2
(lower) expression at various stages of mammary gland maturation (as indicated at top: V, virgin; Preg, pregnant; Lact, lactation; Reg, regressing). Samples
were normalized to -actin RNA (data not shown), except during lactation, when the RNA levels of the milk protein genes skewed the total RNA population.
Note that two to three mice were used for the virgin and regression stage RNA samples, while one mouse was utilized for the other stages. (B–G) Detection
of AP-2 protein expression in the mouse mammary gland. The presence of AP-2 (brown) was detected in cell nuclei by using the 3B5 monoclonal antibody
Fig. 2. The expression of -galactosidase in the mammary glands of mice heterozygous for the AP-2 lacZ knock-in allele. The detection of -galactosidase activity
was performed on whole- mount preparations (A, C, E, G), and subsequently visualized in cross-section (B, D, F, H). Mammary glands were derived from mice
at 5 weeks of age (virgins; A and B); at 10 days of pregnancy (C and D); at 7 days of lactation (E and F); and during regression, 7 days after weaning (G and H).
(B–D). AP-2 protein was visualized by using the 96 polyclonal antiserum (E–G). Sections shown are ductal tissue (B, E) and terminal end bud structures
(C, F) from a 7-week virgin mouse; and alveolar tissue from a mouse at 14 days of pregnancy (D, G). Body cells (arrow) and cap cells (arrowhead) of the
terminal end bud are marked in (C) and (F).
stained with nuclear fast red. The generation and character-
ization of mice containing the AP-2 lacZ knock-in allele
have been described elsewhere (Brewer et al., 2002).
Antibodies and immunohistochemistry
Immunohistochemical analysis of endogenous AP-2 pro-
tein expression was performed by using either an AP-2-
specific monoclonal antibody (3B5) or an AP-2-specific
polyclonal antiserum (96), as previously described (Turner
et al., 1998; Zhang et al., 1996). The analysis of transgene
expression was performed by using the polyclonal anti-
serum SC-807 (Santa Cruz), which recognizes the FLAG
epitope tag. Sections were incubated with a 1:100 dilution
of SC-807 overnight at 4°C and subsequently processed for
reactivity by using the avidin–biotin peroxidase technique
(Vectastain ABC Kit; Vector Laboratories). The assessment
of cell proliferation in mammary tissue was performed by
using the Phosphohistone H3 (Ser10) (6G3) (Cell Signaling
Technology) mouse monoclonal antibody in combination
with the M.O.M. blocking procedure (Vector Laboratories)
as recommended by the manufacturer. Subsequently, sec-
tions were incubated for 30 min in a solution of 1 PBS and
0.05% Triton that contained Alexa Fluor 488 goat anti-
rabbit IgG and Alexa Fluor 594 goat anti-mouse IgG (Mo-
lecular Probes). Images were captured on a SPOT 2 digital
camera by using a Leica microscope with fluorescence op-
tics, and were manipulated in Adobe Photoshop. Cell pro-
liferation was also measured by using the “BrdU Cell Pro-
liferation Assay” (Oncogene Research Products). Briefly,
13.5-day or 18.5-day pregnant transgenic or wild-type mice
were injected with bromodeoxyuridine solution (50 mg/kg,
i.p.) and euthanized 2 h later. The fourth inguinal mammary
gland was isolated and fixed in 4% paraformaldehyde. Fol-
lowing immunological detection of BrdU on sectioned ma-
terial, the number of BrdU-positive cells per 1000 epithelial
cells was counted from 5 different randomly chosen areas in
the mammary gland tissue sections, and the data were an-
alyzed by using the Student’s t test.
For apoptotic cell analysis, frozen sections were cut at 12
M and mounted on poly-L-lysine-coated slides. The
TUNEL assay was performed by using the “In Situ Cell
Detection Kit” (Boehringer Mannheim) or the “FrageEL
DNA Fragmentation Kit” (Oncogene Research Products),
and slides were then counterstained with nuclear fast red.
Data were quantitated as above for the BrdU-labeled tissue.
Construction of transgenes
Transgenes were constructed by using standard subclon-
ing techniques. The plasmid SPRSV-AP2 (Williams and
Tjian, 1991a) was used as a starting vector for attachment of
a sequence encoding a FLAG epitope tag to the 3 end of the
human AP-2 cDNA. Specifically, the sequence 5- GGC
GGC GAT TAC AAA GAC GAC GAT GAT AAA TAG
GAA TTC CTC GAG -3 was used to replace the normal
TGA stop codon as well as the 3 flanking sequences up
until the XhoI site, which is present in the adjacent
polylinker. The new plasmid, termed SP(RSV)AP-2 FLAG,
encodes a version of AP-2 in which the normal 437-
amino-acid protein is extended by 10 residues (gly gly asp
tyr lys asp asp asp asp lys Stop), of which the final 8 encode
the FLAG epitope. This tag enables expression of the trans-
gene to be distinguished from the endogenous gene at the
level of RNA and protein expression. The AP-2 FLAG
fusion construct was then placed under the control of mouse
mammary tumor virus long terminal repeat (MMTV LTR).
The SP(RSV)AP-2 FLAG plasmid possesses a second
polylinker sequence immediately upstream of the AP-2
cDNA open reading frame. A HindIII site is present at the
5 end of this polylinker, and an initiator codon occupies the
last three nucleotide positions, 5-AAG CTT GAA TTC
GGT ACC CGC CAT G-3. The SP(RSV) AP-2 FLAG
plasmid was digested with the restriction enzyme HindIII
and subsequently repaired with T4 DNA polymerase in the
presence of dNTPs. The AP-2 cDNA insert was then
removed by digestion with XhoI and placed between the
SmaI and XhoI sites of the plasmid pMSG (Amersham
Pharmacia) to generate the plasmid MSG AP-2 FLAG. The
fidelity of the construct was confirmed by DNA sequence
analysis. For microinjection, MSG AP-2 FLAG was di-
gested with HindIII and XbaI restriction enzymes, and the
fragment corresponding to the transgene was then separated
from vector sequences by sucrose density gradient ultracen-
trifugation. The fractions that contained the transgene frag-
ment were collected and dialyzed extensively against 10
mM Tris–Cl, 0.25 mM EDTA, pH 7.5, and the DNA con-
centration was adjusted to 2 g/ml prior to microinjection.
Generation of transgenic mice
Transgenic mice were generated by injecting DNA into
pronuclei of fertilized eggs of inbred FVB mice (Taconic).
The embryos surviving the microinjection were transferred
into the oviducts of pseudopregnant females (CD1 strain;
Charles River). After birth, founders carrying the transgene
were identified by Southern blot analysis of genomic DNA.
The offspring of the founders carrying the transgene were
identified by PCR. Transgene expression was monitored by
RNase protection of total RNA isolated from mammary
tissue of 14-day pregnant mice.
Isolation of genomic DNA, southern blot, and PCR
analysis
Genomic DNA was isolated from tails of 3- to 4-week-
old mice as described (Laird et al., 1991). A 12-g aliquot
of genomic DNA was digested with the restriction enzyme
BglII, electrophoresed on a 0.8% agarose gel, and trans-
ferred to nitrocellulose (Schleicher & Schuell) or Hybond N
filters (Amersham). The filter was hybridized with a SmaI–
NcoI fragment corresponding to nucleotides 557 to 1290 of
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the human AP-2 cDNA (Williams et al., 1988). This DNA
fragment was either radioactively labeled by random-prim-
ing in the presence of 32P dATP, or labeled nonradioactively
with the “Genius Nonradioactive Nucleic Acid Labeling
and Detection Kit” (Boehringer-Mannheim). The hybrid-
ized products were visualized by autoradiography or by
light-emission, respectively. PCR was performed by using
forward primer MMTV-5 (corresponding to MMTV LTR
nucleotides 7591–7611 in the plasmid pMSG): 5-TCA
CAA GAG CGG AAC GGA CTC-3, and reverse primer
TWY3 (corresponding to positions 128-111 of the human
AP-2 cDNA): 5-GCT GGT GCC GTC GTC ACG-3.
PCR conditions were: 1 cycle at 94°C for 1 min 20 s; 32
cycles at 94°C for 45 s, 53°C for 45 s, 72°C for 2 min; and
1 cycle at 72°C for 10 min. A fragment of 320 bp was
amplified from mice containing the transgene.
Isolation of RNA, RNase protection, and in situ
hybridization
Mouse mammary tissue was homogenized in guanidine
isothiocyanate buffer, and the total RNA was isolated as
described (Chomczynski and Sacchi, 1987). RNase protec-
tion was performed essentially as published (Williams et al.,
1988), except that 10 g of total RNA was used for each
protection assay. Riboprobes specific for transcripts corre-
sponding to the human AP-2 transgene, or the endogenous
mouse AP-2, AP-2, or AP-2 genes, were generated
from the following four plasmids. The plasmid TRIP1 con-
tains the mouse AP-2 cDNA sequences corresponding to
amino acids 97 to 437 inserted between the HindIII and
EcoRI sites of pBS II KS (Stratagene). The plasmid
JSmu5 contains the mouse AP-2 cDNA sequences cor-
responding to amino acids 66 to 214 inserted between the
HindIII and Acc65I sites of pBS II SK (Stratagene). The
plasmid mu--3 contains the mouse AP-2 cDNA se-
quences corresponding to amino acids 364 to 449 inserted
between the HindIII and KpnI sites of pBS II SK (Strat-
agene). The plasmid P4 contains the human AP-2 cDNA
corresponding to amino acids 1 to 437, and the sequences
encoding the C-terminal FLAG epitope tag, inserted be-
tween the EcoRI and XhoI sites of pBluescript SK (Strat-
agene). TRIP1, JSmu5, mu--3, and P4 were linearized
with MluI, XbaI, HindIII, and NcoI, respectively, and the
cRNA probes were synthesized with T7 RNA polymerase in
the presence of 32P UTP. The protected fragments were
580 nt for AP-2, 450 nt for AP-2, 300 nt for AP-2, and
150 nt for the human transgene. The riboprobe specific for
the transgene incorporated sequences corresponding to the
FLAG epitope tag, as well as a 120-nt fragment of the 3
end of human AP-2 cDNA (see Fig. 3). A 380-bp mouse
PTHrP cDNA fragment, corresponding to nucleotide posi-
tions 121–501 of exon 5 (from GenBank Accession No.
M60057), was derived from total cellular RNA of 12- day
pregnant mammary tissue by RT-PCR using the primers
5-TG GAA TTC CAA GGA CAC GTT ACA GGA TT-3
(forward) and 5-CAT GAA TTC ATG CAC AGA AGG
AAA TCA GT-3 (reverse). Subsequently, this fragment
was subcloned into the EcoRI site of pBS II KS (Strat-
agene), and an antisense riboprobe was made by using T3
RNA polymerase after linearization with BamHI. A 231-bp
p21waf1/cip1 cDNA fragment, corresponding to nucleotides
20–241 (from GenBank Accession No. U24173), was ob-
tained similarly, using the primers 5-ATTC GAA TTC
GTC AGA GTC TAG GGG AAT TG-3 (forward) and
5-ATCC GGA TCC ACG AAG TCA AAG TTC CAC
CG-3 (reverse). The PCR product was digested with EcoRI
and BamHI and subcloned into the corresponding sites of
pBS II KS (Stratagene). Subsequently, the plasmid was
linearized with EcoRI, and an antisense transcript was ob-
tained by using T7 RNA polymerase. The mouse K18
cDNA was a gift of Dr. Robert Oshima (the Burnham
Institute), and a riboprobe was made by using SP6 RNA
polymerase after the plasmid was linearized with EcoRI.
The -actin control riboprobe was obtained from Ambion,
Inc (Austin, TX). The mouse EGF-R, ErbB2, ErbB3, whey
acidic protein (WAP), - casein, and -lactalbumin cDNAs
were obtained from Drs. Frank Jones and David Stern in the
Department of Pathology at Yale University School of Med-
icine. The ErbB2 and ErbB3 plasmids were both linearized
with BamHI, prior to transcription with T7 RNA polymer-
ase, while the EGF-R plasmid was linearized with HindIII
and transcribed with T3 RNA polymerase. In situ hybrid-
ization with the other plasmids was performed essentially as
described (Jones et al., 1999), except that probes were
radiolabeled by using 33P UTP.
Results
Expression of endogenous AP-2 genes in the mouse
mammary gland
The majority of mammary gland development occurs
during puberty and pregnancy, in response to changes in
hormone levels (Daniel and Silverstein, 1987; Hen-
nighausen and Robinson, 1998). At birth, the mammary
gland consists of a rudimentary network of ducts that oc-
cupies a small region of the fat pad in the vicinity of the
nipple. Outgrowth and bifurcation of the ducts occur in
response to estrogen during puberty. Expansion of the lobu-
loalveolar network and differentiation into a secretory organ
occur in pregnancy and lactation, respectively. Weaning
leads to involution, and the mammary gland is eventually
remodeled to resemble the virgin state. To determine how
the AP-2 genes are regulated during these various stages of
postnatal mammary gland development, we examined both
RNA and protein expression. Transcripts corresponding to
all AP-2 family members, with the exception of AP-2,
were readily detected in mammary tissue (Fig. 1A, and data
not shown). RNase protection analysis indicated that the
AP-2, AP-2, and AP-2 genes were all expressed in a
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Fig. 3. The MMTV-AP-2 transgene. (A) The structure of the MMTV-AP-2 construct. The locations of the PCR primers used to identify transgenic progeny
(arrows), and of the cRNA probe used for the RNase protection analyses (underlined), are shown. (B) RNase protection analysis of transgene expression in
the mammary tissue of transgenic founder offspring. The numbers refer to the identity of the founder mice. (C–F) Detection of transgene protein expression
using a polyclonal antiserum specific for the FLAG epitope tag. Mammary tissues were derived from normal mice (C, E) or from siblings that possessed the
MA44 transgene insertion (D, F). Mammary tissues were obtained from 6-month-old virgin mice (C, D) and mice at 14 days of pregnancy (E, F). The
locations of ductal and alveolar epithelial cells are indicated, respectively, by arrows and arrowheads.
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similar manner at various stages in the growth of the mam-
mary gland (Fig. 1A, and data not shown). Transcripts from
all three genes were readily detected in the early virgin
mammary tissue, and expression levels continued to in-
crease as the mammary gland matured. Higher levels of
AP-2 expression were observed in pregnant mammary tis-
sue. As gestation progressed, the expression of all three
AP-2 genes continued to increase and reached a peak at 15
days of pregnancy, the latest pregnant mammary tissue
analyzed. The expression of these genes was sharply re-
duced in lactating mammary tissue, but expression was
reactivated during the stage of involution.
We next utilized immunological reagents specific for
AP-2 and AP-2 to examine the mammary gland cell
types in which these two AP-2 proteins were expressed
(Turner et al., 1998; Zhang et al., 1996). Immunohistochem-
ical analysis with these reagents revealed that both the
AP-2 and AP-2 transcription factors were localized in the
nuclei of the ductal epithelium of the virgin mouse mam-
mary gland (Fig. 1B and E). Staining for both proteins was
also apparent in the body cells of the terminal end buds (Fig.
1C and F). At later stages, the presence of AP-2 and
AP-2 could also be observed in the alveolar epithelium of
pregnant mice (Fig. 1D and G). The AP-2 proteins were
reduced to an undetectable level in the lactating mammary
gland, but became evident again during involution (data not
shown). The AP-2 protein was expressed in a similar
developmental profile in the ductal and alveolar epithelia,
although in this instance, detailed examination was not
possible with the available immunological reagents (data
not shown). Together, these data show an excellent corre-
lation with the RNase protection analyses concerning the
developmental profile of AP-2 expression in the mouse
mammary gland. However, there were qualitative differ-
ences between the expression of AP-2 and AP-2. First,
during the initial phase of lactation, AP-2 transcripts were
maintained at higher levels than AP-2 transcripts. Second,
in both virgin and pregnant animals, the AP-2 protein was
Fig. 4. Morphology of transgenic mammary glands from virgin mice. Whole-mount preparations are shown of the fourth inguinal mammary gland of either
normal mice (A, C, and E), or transgenic siblings (B, D, and F). Mammary glands are from 8-week-old virgin mice (A, B) or from virgin mice at 6 months
of age (C–F). The dark oval in the center of the gland is a lymph node. (E, F) Higher magnifications of the periphery of the glands shown in (C) and (D).
Arrows indicate alveolar buds.
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present in the majority of ductal and alveolar epithelial cells.
In contrast, AP-2 was expressed in approximately 70–
80% of the virgin ductal epithelial cells and displayed var-
iegated expression in the alveolar clusters during preg-
nancy. Further differences between AP-2 and AP-2
expression were observed in the terminal end buds (TEBs).
These structures are responsible for the outgrowth of the
ductal network into the surrounding fat pad. Two cell pop-
ulations, termed cap cells and body cells, have been iden-
tified within the TEB. Cap cells will form the myoepithelial
layer, and body cells will form ductal epithelial tissue. The
AP-2 protein was present in the majority of both the body
(Fig. 1C, arrow) and cap cells (Fig. 1C, arrowhead), al-
though the latter cells had lower expression levels. AP-2
was also present in both body and cap cells. However,
AP-2 was present within fewer cells of the TEB, and the
level of expression within an individual body cell (Fig. 1F,
arrow) or cap cell (Fig. 1F, arrowhead) was equivalent.
We have recently generated a mouse strain in which the
bacterial lacZ gene is inserted in- frame into the coding
region of the AP-2 gene locus (Brewer et al., 2002). Mice
that are heterozygous for this allele are viable and fertile and
provide an additional means by which the expression profile
of the AP-2 locus can be followed during postnatal devel-
opment of the mammary gland. In these mice, -galactosi-
dase activity is detected in the ductal epithelium and TEBs
of virgin animals, and continues to be expressed in the ducts
and lobuloalveoli during pregnancy (Fig. 2A–D). Expres-
sion of the AP-2 lacZ allele is undetectable during lacta-
tion, but -galactosidase activity is restored during regres-
sion (Fig. 2E–H). These results provide an independent
confirmation of our previous findings concerning the spatial
and temporal expression pattern of the AP-2 gene in the
postnatal mammary gland.
Generation and characterization of AP-2 transgenic
mouse lines
The dynamic expression profile of the AP-2 proteins in
the mammary gland suggested that these transcription fac-
tors could be involved in regulating gene expression during
mammary gland growth and morphogenesis. We utilized a
transgenic approach to test this hypothesis. The human
AP-2 cDNA was placed under the control of the MMTV
LTR (Fig. 3A), and injected into one- cell mouse embryos.
The human and mouse AP-2 proteins are almost identical
at the protein level, differing by only 1 out of 437 amino
acids. The utilization of the human transgene ensured that
its expression would be readily distinguished from the en-
dogenous mouse gene by RNase protection analysis. We
also attached a FLAG epitope tag to the C terminus of the
transgene, and this tag enables the protein derived from the
transgene to be distinguished from the endogenous AP-2
protein. Ten transgenic founder mouse lines were generated
as assessed by Southern blot analysis. To examine transgene
expression, RNase protection assays were performed on
offspring of the MMTV AP-2 founders by using total
RNA isolated from mammary tissue of 14-day pregnant
mice. Seven of these transgenic lines expressed significant
levels of the human AP-2 transgene in the mammary
glands (Fig. 3B), and three lines, MA7, MA14, and MA44,
were kept for further analysis. We also determined that, in
these three lines, lower levels of transgene expression oc-
curred in the lung, salivary gland, and kidney, but no ex-
pression was detected in the ovaries (data not shown). With
the exception of the mammary gland phenotype discussed
below, no gross anatomical differences between transgenic
mice and their wild-type littermates were detected in any
tissue.
We next utilized immunohistochemistry to examine the
relative expression levels of the transgene in the various
mammary gland cell populations of the MA44 transgenic
mice and nontransgenic siblings (Fig. 3C–F). Mammary
tissues taken from both virgin and pregnant mice were
probed with a polyclonal antiserum specific for the FLAG
epitope tag. Transgene expression was clearly detected in
both ductal (arrows) and alveolar (arrowheads) epithelial
cells of the MA44 mouse line (Fig. 3D and F). In contrast,
transgene product was not detected in these cell types in
nontransgenic sibling mammary tissue (Fig. 3C and E).
Note that expression of the transgene was found to be
nonuniform in the ductal epithelia of the mammary gland at
various stages of development (for example, Fig. 3D). Var-
iegated expression is frequently seen for mammary gland
transgenes driven by the MMTV, WAP, or -lactoglobulin
promoters (Barash et al., 1999; Deckard-Janatpour et al.,
1997; Faerman et al., 1995; Jones and Stern, 1999; Jones et
al., 1999; Robinson et al., 1995). There is also evidence that
endogenous genes, such as the progesterone receptor and
those encoding milk proteins, are not uniformly expressed
in all cells of the ductal or lobuloalveolar epithelium of the
mouse mammary gland (Robinson et al., 1995; Silberstein
et al., 1996). Therefore, the differential transgene staining
we observe is not atypical. Nevertheless, the mosaic nature
of our transgene’s expression does preclude a straightfor-
ward morphometric analysis of the mammary gland as a
whole.
Overexpression of AP-2 inhibits alveolar budding in the
virgin mouse mammary gland
As shown above, the analysis of the FLAG-stained tissue
from virgin and pregnant mice indicated that we had been
successful in targeting the AP-2 transgene to the appro-
priate mammary epithelial layers. It was also evident from
an examination of the sections at lower magnification that
there was a reduced amount of epithelial tissue in the mice
that overexpressed AP-2 compared with their wild-type
siblings (data not shown, and see below). To determine
further the effects of overexpression of AP-2, mammary
glands from virgin, pregnant, and lactating mice were ex-
amined by whole-mount analysis. All three transgenic lines
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studied in our analysis (MA44, MA14, and MA7) generated
a similar mammary gland phenotype (data not shown).
Since the MA44 transgenic line produced the most pro-
nounced alterations in morphology, mammary glands from
these mice were studied in detail. The initial phase of
postnatal mammary gland development, involving ductal
outgrowth through the mammary fat pad, was not affected
in the transgenic mice. Indeed, a comparison of whole-
mount mammary gland tissues from a normal littermate
(Fig. 4A) and a transgenic mouse (Fig. 4B) at 8 weeks of
age indicated that the ductal network had filled the entire fat
pad in both instances. In older virgin mice, however, there
was a dramatic difference in the morphology of the ducts.
At 6 months of age, the ductal system of a normal littermate
had a highly branched organization that was associated with
multiple alveolar bud structures (Fig. 4C and E, arrows). In
contrast, mammary glands from the transgenic mice dis-
played a simpler, sparser, ductal network. While there was
no alteration in the number of major side-branches, we
noted a dramatic reduction in the frequency of the alveolar
buds (Fig. 4D and F, arrows).
Overexpression of AP-2 causes defects in lobuloalveolar
development during pregnancy and lactation
Subsequent examination of the transgenic mice during
pregnancy demonstrated significant underdevelopment of
the lobuloalveolar structures when compared with their non-
transgenic littermates. By day 15 of pregnancy, the normal
mammary gland had developed well-formed alveoli (Fig.
5A and C, arrows). In contrast, the transgenic gland had far
fewer alveoli, and these were smaller and more compact
(Fig. 5B and D, arrows). Strikingly, ducts were clearly
visible in whole-mount preparations of transgenic mam-
mary glands (Fig. 5D, arrowheads), whereas these structures
were obscured by lobuloalveolar expansion in normal con-
trol mice. Histological examination confirmed that trans-
genic mice had fewer clusters of lobuloalveoli, and showed
that each individual alveolus was smaller and more con-
densed as compared with the normal littermate (Fig. 5E and
F). Moreover, in contrast to the abundant presence of cel-
lular and luminal lipids in normal littermates at this stage
(Fig. 5E, red arrows), we did not observe the accumulation
of such lipids in the lobuloalveoli of transgenic mice (Fig.
5F).
We next examined whether the decreased quantity of
lobuloalveolar tissue in the transgenic mice resulted from
alterations in cell death and/or cell proliferation. The
TUNEL assay was used to examine the incidence of cell
death in the mammary glands of wild type and transgenic
mice at 13.5 and 18.5 days of pregnancy (Table 1, and data
not shown). Few apoptotic cells were observed in the wild
type mammary epithelial tissue at either time point (0.38
and 0.16% cells, respectively), but there was a significant
increase in apoptosis at both stages of mammary gland
development in the transgenic mice (0.96 and 0.5% cells,
respectively). In the transgenic mammary glands, apoptotic
cells were often found in regions that contained the charac-
teristic compact alveolar tissue described above (data not
shown). We next determined the distribution of proliferat-
ing cells after 2 h of BrdU labeling in wild type and
transgenic mammary glands at 13.5 and 18.5 days of preg-
nancy (Table 2). In both strains of mice, the greatest num-
bers of labeled cells were observed at the 13.5-day time
point, when the alveolar network is rapidly increasing in
size. However, at this time point, nontransgenic mammary
glands displayed two- to threefold greater levels of prolif-
erating cells than their transgenic counterparts. Similar dif-
ferences in proliferation between the two strains of mice
were also observed at 18.5 days of pregnancy. We also
examined cell proliferation in the wild type and transgenic
animals using immunohistochemistry for the phosphohis-
tone H3 cell proliferation marker. Again, we found that
there were more labeled cells in wild-type than transgenic
mammary glands at these two time points and the quiescent
state tended to coincide with regions of high transgene
expression (data not shown). Note that the differences seen
in proliferation and apoptosis between wild type transgenic
mice probably underestimate the influence of ectopic AP-2
expression on these cellular processes since the MA44
mammary glands are mosaic, not uniform, with respect to
transgene expression. Taken together, these findings indi-
cate that the reduction in lobuloalveolar tissue in the trans-
genic mice results from a combination of decreased prolif-
eration and increased cell death.
Morphological differences between the mammary glands
of transgenic and control mice were also apparent during
lactation (Fig. 6). Whole-mount staining performed at 1 day
postpartum revealed an extensive secretory network in nor-
mal mice, in which lobuloalveoli were expanded due to the
presence of lactation products (Fig. 6A). In contrast, the
lobuloalveoli of transgenic mice were sparser and remained
more condensed (Fig. 6B). One consequence of the under-
developed lobuloalveolar structures is that the ducts were
still clearly visible in the transgenic mice compared with
their normal siblings (Fig. 6B, blue arrows). The ducts
themselves had a similar distended appearance in both wild-
type and transgenic animals, consistent with milk secretion
(see below). Histological analysis at 1 day postpartum re-
vealed further differences between wild-type and transgenic
mammary glands. First, more lobuloalveolar clusters were
present in the normal mammary glands (Fig. 6C) than in
sibling transgenic mice (Fig. 6D). Second, alterations were
also apparent with respect to the overall architecture of the
mammary gland and lobuloalveolar morphology. In control
animals, the lobuloalveolar lumens were engorged with
lactation products, and the alveolar epithelial cells had a
flattened morphology, indicating that these cells had under-
gone secretory differentiation (Fig. 6C). Moreover, al-
though there was a limited degree of heterogeneity in the
control animals, the lobuloalveolar structures from these
mice were generally uniform in appearance throughout the
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gland. In contrast, the mammary glands from transgenic
mice displayed considerable heterogeneity in the morphol-
ogy of the lobuloalveoli (Fig. 6D). A subset of the gland
contained alveolar epithelial cells typical of this maturation
stage (Fig. 6D, arrows), although sometimes the lumens in
these regions could be more distended, a phenotype also
noted for mice carrying a dominant negative FGFR2 trans-
gene (Jackson et al., 1997). However, other regions of the
gland appeared to be at an earlier stage in the maturation
process, since alveolar cells were more cuboidal in shape,
and the lumens contained lower amounts of lactation prod-
ucts (Fig. 6D, arrowheads).
Fig. 5. Morphology of transgenic mammary glands at 15 days of pregnancy. (A–D) Whole-mount preparations are shown of the fourth inguinal mammary
gland from either a normal mouse (A, C) or a transgenic sibling (B, D). (C, D) Higher magnifications of the periphery of the glands shown in (A) and (B).
Arrows indicate alveoli, and arrowheads show ducts. (E, F) Histology of mammary tissue taken from a normal mouse (E) or from a transgenic sibling (F).
Red arrows indicate intracellular lipids; red arrowheads indicate condensed lobuloalveoli.
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By 7 days postpartum, lobuloalveolar lumens were
prominent throughout the whole mammary pad of nontrans-
genic mice (Fig. 6E). Histological sections of these normal
mice indicated that stromal fat cells were rarely observed
and that the lobuloalveolar lumens were engorged with
secretory proteinacious materials (Fig. 6E, red arrows). In
contrast, fat cells were still readily apparent in the trans-
genic mammary glands at 7 days postpartum (Fig. 6F,
Fig. 6. Morphology of postpartum transgenic mammary glands. (A, B) Whole-mount preparations are shown of the fourth inguinal mammary gland of a
normal mouse (A), or a transgenic sibling (B), at 1 day postpartum. Blue arrows indicate ducts. (C, D) Histology of the mammary tissue shown in (A) and
(B), respectively. Arrows show tissue that has a normal appearance for this stage of mammary gland maturation, and arrowheads indicate tissue that is less
well-developed. (E, F) Histology of mammary tissues taken from 7 days postpartum normal (E), or transgenic (F), sibling mice. Red arrows indicate secretory
proteinacious material; red arrowheads show lipids within the immature epithelial cells; and the asterisk identifies fat cells. Pups were removed from the
mothers 5–6 h before sacrifice and mammary gland isolation.
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asterisk). Furthermore, some alveolar epithelial cells from
the transgenic mice still retained a cuboidal shape, and large
intracellular fat droplets were still visible (Fig. 6F, red
arrowheads), features which are more typical of late preg-
nancy (Hollmann, 1969). Despite the variegated phenotype,
the AP-2 transgenic mothers were able to feed litters of
normal size, indicating that sufficient milk production is
occurring.
Analysis of gene expression during pregnancy and
lactation
Interestingly, the mammary glands of transgenic mice
that overexpressed dominant negative versions of ErbB2 or
ErbB4 also contained regions in which alveolar clusters
more typical of late pregnancy were present during lactation
(Jones and Stern, 1999; Jones et al., 1999). However, the
influence of these two transgenes on lactogenesis could be
distinguished by their influence on milk protein gene ex-
pression. Therefore, we further investigated the effect of
exogenous AP-2 on mammary gland development by ex-
amining the expression of three molecular markers of lac-
tation: whey acidic protein, -lactalbumin, and -casein. In
situ hybridization studies were performed on serial sections
of wild-type and transgenic mammary tissue at 1 day post-
partum, and the results were compared with the presence of
the FLAG epitope on adjacent sections. FLAG epitope
staining revealed that exogenous AP-2 protein was present
throughout the transgenic gland, in both the cuboidal epi-
thelial cells and the more flattened epithelial cells (Fig. 7,
and data not shown). However, the level of transgene ex-
pression was variable within an individual gland, with a
tendency for higher levels of FLAG reactivity to occur in
the epithelial cells with the less mature, cuboidal, morphol-
ogy. In situ hybridization studies were performed by using
sense and anti-sense probes specific for the three milk pro-
tein genes. No significant hybridization was observed with
the sense probes (data not shown). Data obtained using the
anti-sense probes indicated that these three milk protein
genes were expressed almost uniformly in both transgenic
mice (Fig. 7) and wild-type mice (data not shown). Notably,
in the transgenic mice, uniform expression of these genes
occurred despite the distinct lobuloalveolar morphologies
present in different regions of the gland. Taken together,
these findings indicated that the overexpression of AP-2
could alter lobuloalveolar morphology but did not prevent
transcription of the major milk protein genes.
Next, we investigated the mechanism by which the over-
expression of AP-2 might influence the postnatal devel-
opment of the mammary gland. The expression of several
genes known to regulate the growth and morphogenesis of
the mammary gland and/or postulated to be AP-2 targets
were examined in 12-day pregnant wild-type and transgenic
mice, using a combination of RNase protection and semi-
quantitative RT-PCR analyses (Fig. 8, and data not shown).
These studies revealed an 3-fold increase in the RNA
levels for the parathyroid hormone-related protein (PTHrP)
in the mammary glands of transgenic mice compared with
their wild-type littermates (Fig. 8). The increase in PTHrP
expression was also observed by using semiquantitative
RT-PCR (J.Z., data not shown). Previous studies have
shown that the PTHrP promoter is directly activated by
AP-2 in vitro (Prager et al., 1994). Moreover, mice that
express a PTHrP transgene in the mammary gland also
display an inhibition of development (Wysolmerski et al.,
1995). Therefore, the increase in PTHrP expression seen in
the AP-2 transgenic mice represents a plausible mecha-
nism by which mammary gland morphology is altered in
these animals. In contrast to the changes in PTHrP expres-
sion, we did not detect any differences in transcript levels
between transgenic mice and wild-type littermates for three
further potential AP-2 target genes, p21waf1/cip1, ErbB2, and
ErbB3 (Fig. 8). We also found no significant alteration in
the expression of several additional genes which encode
growth factor signaling molecules associated with mam-
mary gland morphogenesis, including wnt4, the progester-
one receptor, the prolactin receptor, EGF-R, and ErbB4
(Fig. 8, and data not shown).
Table 1
Comparison of apoptosis levels in mammary epithelial cells between
transgenic and wild type mice
No. apoptotic cells per 1000
at 13.5 days of pregnancy at 18.5 days of pregnancy
MA44 transgenic Nontransgenic MA44 transgenic Nontransgenic
8 4 6 2
10 2 4 0
11 6 8 4
7 3 3 1
12 4 4 1
Average 9.6 Average 3.8 Average 5 Average 1.6
0.96% 0.38% 0.5% 0.16%
Note. Student’s t test probability at 13.5 days: P  0.001; at 18.5 days:
P  0.0004.
Table 2
Comparison of proliferation levels in mammary epithelial cells between
transgenic and wild type mice
No. proliferating cells per 1000
at 13.5 days of pregnancy at 18.5 days of pregnancy
MA44 transgenic Nontransgenic MA44 transgenic Nontransgenic
21 42 4 11
30 36 8 17
17 48 2 20
23 56 5 14
19 47 6 16
Average 22 Average 45.8 Average 5 Average 15.6
2.2% 4.6% 0.5% 1.6%
Note. Student’s t test probability at 13.5 days: P  0.0003; at 18.5 days:
P  0.016.
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Discussion
Previous studies have demonstrated that the AP-2 family
of transcription factors regulates multiple aspects of mam-
malian development. Formation of the neural tube, face,
eyes, limbs, heart, ventral body-wall, and kidneys all rely
upon the appropriate expression of the AP-2 genes during
mouse embryogenesis (Brewer et al., 2002; Moser et al.,
1997a; Nottoli et al., 1998; Schorle et al., 1996; West-Mays
et al., 1999; Zhang et al., 1996). The observation that the
human AP-2 genes are also expressed in both benign mam-
mary epithelial tissue and early stage breast cancer indicated
that these transcription factors might also be important for
regulating the growth and morphogenesis of the postnatal
mammary gland (Gee et al., 1999; Turner et al., 1998). Our
current studies, in which we have first examined the expres-
sion profile of the AP-2, AP-2, and AP-2 genes in the
postnatal mouse mammary gland, and subsequently manip-
ulated the levels of the AP-2 protein in this organ, strongly
support this hypothesis.
The spatiotemporal expression pattern of the AP-2 gene
family throughout mouse mammary gland maturation and
remodeling was determined by using a combination of
RNase protection, immunohistochemistry, and lacZ gene
knock-in technology. These complimentary techniques in-
dicated that all three genes were present in the ductal epi-
thelia of the postnatal mouse mammary gland, but showed
that they were not expressed in the surrounding myoepithe-
lium. These findings support our previous contention that
the AP-2 proteins are a regular component of the gene
network expressed in normal human breast epithelial tissue
(Turner et al., 1998). However, in our previous studies using
human tissue samples, it was not possible to assess the
expression profile of the AP-2 genes at specific stages of
development. Using the mouse model system, we now show
that expression of all three AP-2 genes occurs in the virgin
mammary gland. AP-2 expression increases in the virgin
gland during the period of ductal outgrowth and continues
to rise during pregnancy as lobuloalveolar development
proceeds. Comparison with cytokeratin expression indi-
cated that the general rise in AP-2 expression reflected the
large increase in mammary ductal epithelial tissue during
these growth periods and was not caused by increased AP-2
levels in individual cells (J.Z., unpublished observations). In
contrast, it is clear that AP-2 expression drops off dramat-
ically in the mammary epithelial cells during lactation,
before it is reactivated with the remodeling of the mammary
gland that occurs during involution. Detailed examination
indicated that the AP-2 and AP-2 proteins were not only
present in the ductal epithelial tissue, but were also found
within the TEBs. Significant AP-2 expression occurred in
the majority of the TEB body cells, while much lower levels
were apparent in cap cells. In contrast, AP-2 expression
was apparent in a subpopulation of both the body cells and
cap cells. Differences in the distribution of AP-2 and
AP-2 proteins within these TEB regions indicate that they
may perform distinct functions in the growth and morpho-
genesis of the ductal network. One possibility is that high
levels of AP-2 are consistent with a body cell and ductal
epithelial cell lineage, while the down-regulation and even-
tual loss of AP-2 would mark cap and myoepithelial cells.
Similarly, the differential expression of AP-2 in the TEB
might indicate cells that have different fates with respect to
gene expression, proliferation, or apoptosis (Humphreys,
1999; Seagroves et al., 2000).
The expression profile of the AP-2 genes is similar to
that of several key regulators of mammary gland develop-
ment and maturation. In other development processes, the
AP-2 transcription factors, and in particular AP-2, control
multiple aspects of growth and morphogenesis. We there-
fore wished to determine whether this key regulatory mol-
ecule could also influence the morphology of the mammary
ductal network. Moreover, since the levels of AP-2 are
increased in breast cancer, we wished to ascertain whether
increased levels of AP-2 might lead to mammary tumor
formation. For these purposes, we generated transgenic
mice that overexpressed the AP-2 gene under the control
of the MMTV LTR. Our findings indicate that the overex-
pression of AP-2 causes a unique spatiotemporal sequence
of changes in mammary gland morphology but does not
result in increased tumorigenesis. In some instances, trans-
gene expression in the endocrine organs, especially the
ovaries, can affect mammary gland morphology by chang-
ing circulating hormone levels. However, two lines of evi-
dence indicate that AP-2 is acting autonomously within
the mammary glands of our transgenic mice. First, we did
not detect transgene expression within the ovaries. Second,
the mammary glands examined in our studies displayed
morphological heterogeneity that coincides with transgene
expression. Indeed, the presence of the epitope tag served as
a powerful means by which transgene expression could be
correlated with morphological differences in the gland.
In the transgenic mice, there were no obvious defects in
the outgrowth of the ducts, nor in the bifurcation of the
individual ducts, two processes that occur during puberty in
response to estrogen. However, there was a significant im-
pairment of alveolar bud formation in the mammary glands
of virgin mice. Furthermore, during pregnancy, transgenic
mice had a less extensive ductal network than was observed
in control mice, and the lobuloalveolar cells also remained
condensed and failed to accumulate lipids at the appropriate
time points. One mechanism by which the overexpression
of AP-2 might directly inhibit ductal proliferation is
through increased expression of the p21waf1/cip1 cell cycle
inhibitor, since the human version of this gene is regulated
by AP-2 in vitro (Zeng et al., 1997). However, we were
unable to detect significant changes in the levels of mouse
p21waf1/cip1 in vivo between wild-type and transgenic mam-
mary tissue. Nevertheless, we did note that there was a
significant decrease in cell proliferation in the transgenic
epithelial tissue as measured by BrdU incorporation and the
analysis of markers of cell proliferation, including phospho-
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histone H3. These findings indicate that a reduction in
actively cycling cells in the mammary gland indeed accom-
panied the overexpression of AP-2, and this may in part
account for the phenotype of the transgenic tissue in the
virgin and pregnant animals. Cell death, which is increased
in the presence of the transgene, may act as a second
mechanism by which the lobuloalveolar tissue is reduced in
the transgenic mice. A link between altered levels of AP-2
expression and an increase in cell death has also been
previously noted in both AP-2 and AP-2 knockout mice
Fig. 7. Milk protein gene expression in transgenic mouse mammary glands at 1 day postpartum. (A, C, and E) Immunohistochemical detection of the FLAG
epitope tag. Darkfield images of in situ hybridizations performed with antisense probes corresponding to WAP (B), -casein (D), and -lactalbumin (F) are
presented for adjacent sections.
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(Moser et al., 1997a; Schorle et al., 1996; Zhang et al.,
1996). In these latter instances, it is possible that the in-
crease in cell death results from either inappropriate cell
cycle progression or defective cell:cell signaling. Similarly,
the alterations in cell death and cell proliferation we noted
above may be the direct result of AP-2 overexpression, or
may occur indirectly if AP-2 instead influences the perti-
nent signal transduction pathways for mammary gland de-
velopment. Note that we have recently obtained further
support for the hypothesis that AP-2 can control prolifer-
ation of mammary epithelia from transplantation studies in
which mammary buds derived from AP-2-null embryos or
from heterozygous siblings have been transplanted into the
cleared fat pads of immunodeficient host mice. Preliminary
results indicate an increase in lobuloalveolar structures dur-
ing pregnancy in transplants derived from AP-2-null em-
bryos compared with those obtained from heterozygous
controls (S.B., J. Wysolmerski, and T.W., unpublished ob-
servations). Together, these findings support a model in
which the levels of AP-2 can modulate alveolar density—
the loss of AP-2 expression causes an increase in alveolar
development, whereas excess AP-2 is inhibitory.
Normal side-branching and lobuloalveolar development
rely on the presence of intact progesterone and prolactin
signaling pathways in the ductal epithelia (Robinson et al.,
2000). The misexpression of several additional key regula-
tory molecules, some of which act as targets for these
hormone signaling cascades, can also result in an underde-
veloped ductal network. In particular, such phenotypes can
be caused by a mutation of either cyclin D1, Stat5a, wnt4,
inhibinB, C/EBP, or A-myb (Fantl et al., 1999; Robinson
and Hennighausen, 1997; Robinson et al., 2000; Teglund et
al., 1998; Toscani et al., 1997), or by overexpression of
components of the TGF-, FGF, and parathyroid hormone-
related protein (PTHrP) signaling pathways (Jackson et al.,
1997; Jhappan et al., 1993; Pierce et al., 1993; Wysolmerski
et al., 1995). We have examined several of these genes to
determine whether their transcript levels were altered in
response to the AP-2 transgene. We did not detect any
differences between transgenic mice and their wild-type
littermates with respect to the progesterone receptor, the
prolactin receptor, or wnt4. However, we did observe a
consistent 3-fold increase in transcripts corresponding to
the signaling molecule parathyroid hormone-related protein
(PTHrP) in the transgenic mice. Intriguingly, previous stud-
ies have shown that the overexpression of PTHrP in the
myoepithelial compartment of the mammary gland inhibits
both side-branching in virgin mice and lobuloalveolar de-
velopment during pregnancy (Wysolmerski et al., 1995).
Therefore, it is possible that altered AP-2 levels cause
changes in mammary gland development in part by affect-
ing PTHrP expression, especially since the PTHrP promoter
can be activated by AP-2 in vitro (Prager et al., 1994). In the
future, it will be of interest to determine whether compo-
nents of the PTHrP pathway are indeed downstream targets
for the AP-2 transcription factors. The finding that trans-
genic mice show no change in the expression of other
postulated AP-2 gene targets, such as p21waf1/cip1, could
result from a number of factors. First, the results may reflect
differences in promoter activity measured here in vivo,
versus in vitro, where many of these human targets were
characterized. Alternatively, these findings may indicate
that there are sequence differences between the promoters
of the human and mouse target genes that may alter their
ability to bind and respond to AP-2 (Bates and Hurst, 1997).
Finally, it is also possible that a different AP-2 protein is
required for expression of these target genes or that AP-2
cannot act alone but needs to function in concert with other
AP-2 proteins or other transcription factors that are limiting
in vivo (Turner et al., 1998).
Following parturition, the sparser appearance of the duc-
tal tree in AP-2 transgenic mice also persisted into lacta-
tion. Even at 7 days of lactation, some areas of the gland
were still occupied by lobuloalveolar structures that were
more appropriate for an earlier stage of the differentiation
process, namely late pregnancy or parturition. Note that we
did not detect transgene expression at 7 days of lactation by
either immunohistochemistry or RNase protection in these
altered regions (J.Z., data not shown), a result that has also
been observed for at least one other MMTV transgene
construct (Jones and Stern, 1999). Therefore, we postulate
that the earlier presence of high levels of AP-2 during late
pregnancy has prevented maturation in these areas. We also
hypothesize that regions having lower levels of transgene
expression during pregnancy would instead escape from the
influence of AP-2 and would proliferate and differentiate
appropriately. Different levels of transgene expression
would therefore lead to the observed variegation in the
morphology of the mammary glands. This hypothesis is
supported by the observation that, at 1 day postpartum, there
is a higher incidence of transgene expression in regions of
the mammary gland that are delayed in differentiation com-
pared with areas that are more mature.
We further addressed the differentiation state of the
mammary epithelia by studying the expression of three
molecular markers of lactation: whey acidic protein (WAP),
-casein, and -lactalbumin. Using in situ hybridization, we
found that all three genes were expressed in the transgenic
Fig. 8. Gene expression in normal and transgenic mammary glands at 12
days of pregnancy. The top panel shows RNase protection data for trans-
genic () and wild-type () littermates for the genes indicated above.
Reactions were normalized by simultaneously assaying for the expression
of the mouse K18 gene (bottom panel), a cytokeratin that is expressed in
the mammary epithelium. Each RNA sample was derived from two mice
of the respective genotype.
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mammary gland at 1 day of lactation. Moreover, transcripts
were present not only in the flattened epithelial cells, char-
acteristic of this stage of lactation, but also in the atypical
and morphologically distinct cuboidal epithelial cells. Thus,
our data suggest that, although the MMTV AP-2 transgene
may alter the morphology of the mammary ductal epithe-
lium, it does not inhibit the expression of the major lactation
proteins. A similar relationship between abnormal morphol-
ogy and normal transcript levels of these milk protein genes
is typical of inhibinB knockout mice as well as mice
expressing the dominant negative ErbB2 transgene (Jones
and Stern, 1999; Robinson and Hennighausen, 1997). In
other instances, notably dominant negative ErbB4 trans-
genic mice and mice lacking the STAT5a gene, altered
morphology is accompanied by a decrease in expression of
one or more of the milk protein genes (Jones et al., 1999;
Liu et al., 1997; Teglund et al., 1998). When taken together,
the AP-2 transgenic phenotype has a distinctive combina-
tion of changes in morphology and in gene expression that
distinguish it from other mutations affecting mammary
gland development.
Despite the link between AP-2 protein expression and
human breast cancer, to date we have not detected any
mammary tumors in the MMTV- AP-2 transgenic mice,
many of which have been kept for greater than 18 months.
Indeed, the overexpression of AP-2 suppressed the growth
and development of the ductal network. We therefore pos-
tulate that, in human breast cancer, the rise in AP-2 ex-
pression is not responsible for the inappropriate cell cycle
progression. Instead, we suggest that the activation of the
AP-2 genes in breast cancer represents a failed attempt to
halt cell proliferation. The conclusion that the AP-2 genes
may have an inhibitory role in tumor progression is sup-
ported by recent in vitro and in vivo studies. First, it has
been shown that transfection of AP-2 into HepG2 hepa-
tocarcinoma cells or SW480 adenocarcinoma cells can in-
hibit their growth and tumorigenicity, possibly by activating
the transcription of p21waf1/cip1 (Zeng et al., 1997). Second,
there is a tendency for AP-2 gene expression to be lost
during the process of metastasis in both breast cancer and
melanoma (Bar-Eli, 1999; Gee et al., 1999), while the ec-
topic expression of AP-2 in melanoma cell lines can re-
duce the tumorigenicity of these cells when they are trans-
planted into nude mice (Bar-Eli, 1999).
Considerable amino acid identity exists between the AP-
2, AP-2, and AP-2 proteins, and indeed these transcrip-
tion factors can all bind to essentially the same recognition
site (Bosher et al., 1996). Nevertheless, human breast cancer
studies indicate that these transcription factors may regulate
different target genes (Gee et al., 1999; Turner et al., 1998).
Subtle differences in the spatiotemporal patterns of AP-2
expression also occur within the mammary epithelium.
Therefore, while the overexpression of AP-2 may be
equivalent to expressing any or all of the AP-2 genes, it is
possible that each gene could perform a unique function
within the mammary gland—a function that is subverted by
the overexpression of one particular family member. Con-
tinued analysis of how these AP-2 genes might act alone or
in concert within the mammary gland is clearly warranted.
In the context of the whole organism, the demonstration that
the AP-2 protein can profoundly influence postnatal mam-
mary gland morphology again illustrates the importance of
this gene family for regulating growth and morphogenesis.
Furthermore, the ability of AP-2 to inhibit lobuloalveolar
proliferation strongly suggests that this gene family can
modulate cell growth in human breast cancer.
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